Matthew Luchini
Stock Analyst at BMO Capital
(1.82)
# 3,124
Out of 4,876 analysts
34
Total ratings
42.11%
Success rate
1.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Luchini
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Maintains: Outperform | $51 → $30 | $9.33 | +221.54% | 4 | Mar 18, 2022 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | $190 | $5.49 | +3,360.84% | 1 | Oct 20, 2021 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $89 → $69 | $17.43 | +295.87% | 3 | Sep 10, 2021 | |
| KOD Kodiak Sciences | Maintains: Market Perform | $138 → $104 | $3.70 | +2,710.81% | 3 | May 11, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | $55 | $1.40 | +3,828.57% | 1 | Mar 31, 2021 | |
| ARVN Arvinas | Initiates: Outperform | $101 | $7.54 | +1,239.52% | 2 | Mar 31, 2021 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $630 | $521.00 | +20.92% | 13 | Jan 25, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Perform | $119 → $124 | $300.75 | -58.77% | 2 | Nov 6, 2020 | |
| GILD Gilead Sciences | Maintains: Market Perform | $74 → $64 | $110.67 | -42.17% | 2 | Oct 29, 2020 | |
| VKTX Viking Therapeutics | Initiates: Outperform | $14 | $26.52 | -47.21% | 1 | Jun 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $47 → $60 | $1.01 | +5,840.59% | 2 | Dec 3, 2019 |
Replimune Group
Mar 18, 2022
Maintains: Outperform
Price Target: $51 → $30
Current: $9.33
Upside: +221.54%
Jasper Therapeutics
Oct 20, 2021
Initiates: Outperform
Price Target: $190
Current: $5.49
Upside: +3,360.84%
Apellis Pharmaceuticals
Sep 10, 2021
Maintains: Outperform
Price Target: $89 → $69
Current: $17.43
Upside: +295.87%
Kodiak Sciences
May 11, 2021
Maintains: Market Perform
Price Target: $138 → $104
Current: $3.70
Upside: +2,710.81%
C4 Therapeutics
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $1.40
Upside: +3,828.57%
Arvinas
Mar 31, 2021
Initiates: Outperform
Price Target: $101
Current: $7.54
Upside: +1,239.52%
Regeneron Pharmaceuticals
Jan 25, 2021
Upgrades: Outperform
Price Target: $630
Current: $521.00
Upside: +20.92%
Madrigal Pharmaceuticals
Nov 6, 2020
Maintains: Market Perform
Price Target: $119 → $124
Current: $300.75
Upside: -58.77%
Gilead Sciences
Oct 29, 2020
Maintains: Market Perform
Price Target: $74 → $64
Current: $110.67
Upside: -42.17%
Viking Therapeutics
Jun 5, 2020
Initiates: Outperform
Price Target: $14
Current: $26.52
Upside: -47.21%
Dec 3, 2019
Downgrades: Market Perform
Price Target: $47 → $60
Current: $1.01
Upside: +5,840.59%